


CURRICULUM VITAE



ANDRÉS L.
ECHAZARRETA

M D PHD

RESUME

CURRICULUM VITAE

ANDRÉS L. ECHAZARRETA

MD PhD



PERSONAL EMAIL

aechaza@gmail.com

WORK EMAIL

andres.echazarreta@centromedicocapital.com.ar



WEBSITE

www.centromedicocapital.com.ar/dr-andres-luis-echazarreta



PHONE

+54 221 4823629

+54 221 4894480

CEL PHONE

+54 2215078358



ADDRESS

Centro Médico Capital
Calle 60 N° 462. La Plata. (B1904AAW)
Buenos Aires. Argentina.

CONFERENCE PRESENTATION

Dr. Andrés L. Echazarreta

- Head of the Respiratory Medicine Service and Medical Director of the Capital Medical Center, La Plata. Argentina
- Former Head of the Pulmonology Service at the San Juan de Dios Hospital in La Plata
- Former President of the Argentine Association of Respiratory Medicine (AAMR)

EDUCATION & TRAINNING

Baccalaureate
(1981)

General Instruction

Baccalaureate. National College from La Plata National University.

MD
(1989)

Medicine

La Plata National University, School of Medicine, Argentina.

Clinician
(1990/94)

Internal Medicine

Resident physician on Internal Medicine, Policlínico San Martín Hospital, La Plata City, Ministry of Health, Buenos Aires, State, Argentina.

Chest Physician
(1994/97)

Respiratory Medicine

Resident in Pneumology, Muñiz Hospital. Ministry of Health, City of Buenos Aires and Buenos Aires University, Argentina.

Pre-doctoral work
(1997)

Asthma

Fellow of the European Respiratory Society, Clinic Hospital of Barcelona, Spain.

Pre-doctoral work
(1998)

Asthma

Fellow of the Spanish Society of Respiratory Pathology, Clinic Hospital, Barcelona, Spain.

Specialist in Pneumology
(1999)

Pneumology

Medical Board of Buenos Aires State, Buenos Aires, Argentina.

PhD
(2005)

Pneumology - Research - Doctoral degree

School of Medicine, Buenos Aires University, Argentina

**Consulting Specialist
in Pneumology**
(2014)

Pneumology

Medical Board of Buenos Aires State, Buenos Aires, Argentina.

CERTIFICATION MEDICAL LICENSURE

ANDRÉS L.
ECHAZARRETA

MD PhD

PROFESSIONAL EXPERIENCE

(1989)	National Medical Licensure 89.816
(1989)	Buenos Aires State Medical Licensure 19.800
Since 2000 (Up to Date)	Medical Staff – Chief of Respiratory Area Instituto de Diagnóstico Cardiovascular La Plata. Buenos Aires. Argentina
2000/2007	Medical Staff Cardiopulmonar Transplant evaluation Area CUCAIBA. Hospital San Juan de Dios. La Plata. Buenos Aires. Argentina
Since 2001 (Up to Date)	Medical Staff Instituto de Diagnóstico de La Plata. Buenos Aires. Argentina
2007/2012	Medical Staff as Chest Physician Respiratory Service. Hospital San Juan de Dios. La Plata. Buenos Aires. Argentina.
2012/2014	Chief of Pulmonary Functional Tests Laboratory Respiratory Service. Hospital San Juan de Dios. La Plata. Buenos Aires. Argentina.
2014/2022	Head of Respiratory Service Hospital San Juan de Dios. La Plata. Buenos Aires. Argentina.
Since 2018 (Up to Date)	Medical Director and Head of Respiratory Unit Centro Médico Capital. La Plata. Argentina. www.centromedicocapital.com.ar

|P2

PROFESSIONAL MEMBERSHIP

(2007/2009)	Tisiology and Pneumonology Society of La Plata City President
(2009/2011)	Tisiology and Pneumonology Society of Buenos Aires Sate President
(2012/2013)	Argentine Respiratory Medicine Association (AAMR) President
(2011/2014)	Argentina in the European Respiratory Society (ERS) National Delegate

AWARDS & RECOGNITIONS

ANDRÉS L.
ECHAZARRETA

MD PhD

(2012) Award "specialist of the year: pneumonology". Recognition of the College of Physicians of the Province of Buenos Aires District I.

(2016) 1st prize for the best epidemiological work. ALAT congress 2016. Santiago de Chile. by: "prevalence of COPD in 4 Argentine cities: the study EPOC.AR.

(2017) Recognition of the trajectory as Former President of the Argentine Association of Respiratory Medicine (AAMR).

RELEVANT FARMACOLOGICAL Research Experience

2001/2002	Protocol in Asthma, phase III, as Principal Investigator
2003/2004	Protocol in asthma, phase III, as Principal Investigator
2004/2005	Protocol in COPD, phase III, as Principal Investigator
2005/2006	Protocol in Asthma, Phase II, as Principal Investigator
2005/2006	Protocol in COPD phase II, as Principal Investigator
2006/2008	Protocol in COPD phase III, as Principal Investigator
2007/2008	Protocol in COPD phase III, as Principal Investigator
2008/2009	Protocol in COPD phase III, as Principal Investigator
2009/2010	Protocol M/34273/34 in COPD phase II, as Principal Investigator
2010/2012	Protocol CCD-0906-PR-0016 in COPD phase III, as Principal Investigator
2012/2014	Protocol ROF-MD-07 in COPD phase III, as Principal investigator
2015/2018	Ethos Study (COPD). Principal Investigator
2020/2021	TACTIC study. Principal Investigator
2023/in progress	Protocol GB44332 in COPD phase III, as Principal Investigator

1. López AM, Abrate VdV, Echazarreta A, Arias S, Del Olmo R, Colodenco F, et al. Superposición Asma-EP-OC: los hallazgos en el estudio EPOC AR. *Revista americana de medicina respiratoria*. 2022;22(2):203-11.
2. Agusti A, De Stefano G, Levi A, Munoz X, Romero-Mesones C, Sibila O, et al. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. *Eur Respir J*. 2022;59(3).
3. Perez TA, Castillo EG, Ancochea J, Pastor Sanz MT, Almagro P, Martinez-Cambolor P, et al. Sex differences between women and men with COPD: A new analysis of the 3CIA study. *Respir Med*. 2020;171:106105.
4. Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernandez ME, et al. Prevalence of Alpha-1 Antitrypsin Deficiency in COPD Patients in Argentina. The DAAT.AR Study. *Arch Bronconeumol (Engl Ed)*. 2020;56(9):571-7.
5. Garcia Castillo E, Alonso Perez T, Ancochea J, Pastor Sanz MT, Almagro P, Martinez-Cambolor P, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. *ERJ Open Res*. 2020;6(4).
6. Horner A, Almagro P, Soriano JB, Kaiser B, Martinez-Cambolor P, Lang D, et al. Risk charts of five-year mortality in COPD patients. *Eur Respiratory Soc*; 2019.
7. Almagro P, Martinez-Cambolor P, Miravittles M, Rodriguez-Carballeira M, Navarro A, Lamprecht B, et al. External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. *COPD*. 2019;16(1):8-17.
8. Guerra B, Haile SR, Lamprecht B, Ramirez AS, Martinez-Cambolor P, Kaiser B, et al. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. *BMC Med*. 2018;16(1):33.
9. Echazarreta AL, Arias SJ, Del Olmo R, Giugno ER, Colodenco FD, Arce SC, et al. Prevalence of COPD in 6 Urban Clusters in Argentina: The EPOC.AR Study. *Arch Bronconeumol (Engl Ed)*. 2018;54(5):260-9.
10. Burgel PR, Paillasseur JL, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, et al. A simple algorithm for the identification of clinical COPD phenotypes. *Eur Respir J*. 2017;50(5).
11. Menga G, Miravittles M, Blanco I, Echazarreta AL, Rossi SE, Sorroche PB, et al. Normativas de diagnóstico y tratamiento del déficit de alfa-1 antitripsina. *Revista americana de medicina respiratoria*. 2014;14(1):28-46.
12. Marquez SE, Echazarreta AL, Macuso MO, Maniago E, Manti AR. Activities during the World Asthma Day in 2012: Its utility for detecting underdiagnosis and undertreatment in asthma patients. *Eur Respiratory Soc*; 2013.
13. Echazarreta DF, Mancini LF, Curró MF, Echazarreta AL, Viscuso C, Portis M, et al. Tratamiento crónico con inhibidores de la PDE-5 en pacientes portadores de insuficiencia cardíaca avanzada. *Insuficiencia cardíaca*. 2008;3(1):16-20.
14. Echazarreta D, Mancini L, Curró M, Echazarreta A, Viscuso C, Portis M, et al. Administración crónica de sildenafil en la hipertensión pulmonar. *Insuficiencia cardíaca*. 2006;1(1):23-7.
15. Echazarreta AL, Rahman I, Peinado V, Barbera JA, Roca J, MacNee W, et al. Lack of systemic oxidative stress during PAF challenge in mild asthma. *Respir Med*. 2005;99(5):519-23.
16. Echazarreta AL, Gomez FP, Ribas J, Sala E, Barbera JA, Roca J, et al. Pulmonary gas exchange responses to histamine and methacholine challenges in mild asthma. *Eur Respir J*. 2001;17(4):609-14.
17. Echazarreta AL, Dahlen B, Garcia G, Agusti C, Barbera JA, Roca J, et al. Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma. *Am J Respir Crit Care Med*. 2001;164(2):202-6.
18. Echazarreta AL, Gomez FP, Ribas J, Achaval M, Barbera JA, Roca J, et al. Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma. *Eur Respir J*. 1999;14(3):616-21.
19. Anzueto A, Cohen M, Echazarreta AL, Elassal G, Godoy I, Paramo R, et al. Delphi Consensus on Clinical Applications of GOLD 2023 Recommendations in COPD Management: How Aligned are Recommendations with Clinical Practice? *Pulm Ther*. 2024;10(1): 69-84.